Trial reportBMC musculoskeletal disorders2025
Non-surgical treatment of anterior cruciate ligament tears with percutaneous bone marrow concentrate and platelet products versus exercise therapy: a randomized-controlled, crossover trial with 2-year follow-up.
Trial report in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01850758 (A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Partial and Complete, Non-retracted Anterior Cruciate Ligament Tears), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Partial and Complete, Non-retracted Anterior Cruciate Ligament Tears
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnterior cruciate ligament (ACL) reconstruction (ACLR) surgery remains the prevailing standard of care for complete ACL ruptures but is not without risk. The aim of this study was to compare non-surgical, autologous bone marrow concentrate (BMC) with platelet products compared to exercise therapy for partial and complete, non-retracted ACL tears without meniscus injuries.
methodsIn this randomized-controlled, crossover trial, patients received either exercise therapy or an injection of BMC with platelet products to treat ACL tears. After 3 months, if patients randomized to the exercise group were not satisfied with their improvement, they could crossover to receive the BMC treatment. Patients reported outcomes were completed at pre-treatment, 1-, 3, 6-, 12-, and 24-months of the Numeric Pain Scale (NPS), the International Knee Documentation Committee (IKDC) subjective knee form, Lower Extremity Function Scale (LEFS), and a modified Single Assessment Numeric Evaluation (SANE). MRIs at pre- and post-treatment were assessed using ImageJ software analysis. Complications and surgeries were assessed at each time point.
resultsPatients in the BMC group reported significantly greater change scores (from pre-treatment) on LEFS (P = 0.027), and SANE (P = 0.007) at 3 months compared to the exercise group. No significant differences were found between baseline and/or 1- month and 3-month follow-ups for any outcome measure (P > 0.05) in the exercise therapy group. When followed through 2 years, patients who received BMC treatment demonstrated sustained improvements in function and decreases in pain, with patients reporting a median of subjective improvement (SANE) of 90% at the final follow-up. Significant negative correlations were found between age of injury and ΔIKDC ΔLEFS, and SANE (P < 0.05) at the 24-month follow-up with lower ΔPROMs reported by those with older tears the age of tear (> 12 months). Post-treatment MRI provided evidence of significant improvements in ACL integrity. No serious adverse events were reported. Four patients did not respond to BMC treatment and underwent ACL reconstruction without any new reports of knee injuries.
conclusionsThe significant improvements in function, pain, and overall improvement in patients receiving BMC and platelets provide evidence of a viable alternative treatment option for patients with ACL tears.
trial registrationNCT01850758; A Randomized Controlled Trial of Regenexx-SD Versus Exercise therapy for Treatment of Partial and Complete, Non-retracted Anterior Cruciate Ligament Tears. Registered May 7, 2013.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.